Definium Therapeutics, Inc. (MMQ0)
XSTU 
Summary
MMQ0 Chart
Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression
Definium Therapeutics NASDAQ: DFTX Chief Medical Officer Dan Karlin said the company's recent Phase III results for DT120 showed statistically significant improvements in generalized anxiety disorder, or GAD, and major depressive disorder, or MDD, following a single treatment, with longer-term open-label portions of the studies still underway.
Definium Therapeutics' DT120 Hits Phase III Goals in Anxiety Study
Definium Therapeutics NASDAQ: DFTX reported positive top-line results from Panorama, its second Phase III study of DT120 ODT 100 mcgs in generalized anxiety disorder, or GAD. The company said the single-dose treatment met its primary endpoint and all key secondary endpoints, adding to positive pivotal-study results previously reported in GAD and major depressive disorder.
Definium Reports Second Phase III Success in Anxiety Disorder Program
DFTX scores a second phase III GAD win as DT120 ODT delivers significant anxiety improvements, paving the way for FDA talks and a planned 2027 regulatory filing.
Definium Therapeutics, Inc. (MMQ0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Definium Therapeutics, Inc. ever had a stock split?
Definium Therapeutics, Inc. Profile
| Pharmaceuticals Industry | Healthcare Sector | Robert Barrow CEO | XSTU Exchange | CA24477V1058 ISIN |
| US Country | 106 Employees | - Last Dividend | 29 Aug 2022 Last Split | - IPO Date |
Overview
Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development of innovative therapies aimed at addressing brain health disorders. The organization is dedicated to advancing novel treatment options for conditions that significantly impact mental well-being. Based in New York, New York, Definium Therapeutics integrates cutting-edge research with rigorous clinical trials to bring forth products that have the potential to improve the quality of life for individuals experiencing various mental health challenges.
Products and Services
- MM120
- MM402
MM120 is currently in phase 3 clinical trials and is designed to address two significant mental health conditions: generalized anxiety disorder and attention deficit hyperactivity disorder (ADHD). By focusing on these prevalent disorders, the company aims to provide effective treatment options that can aid individuals suffering from anxiety-related issues and attention deficits, enhancing their daily functioning and overall quality of life.
MM402 is an R-enantiomer of 3,4-methylenedioxymethamphetamine, which is undergoing phase I clinical trials. This product is specially developed to target the core symptoms associated with autism spectrum disorder (ASD). By exploring innovative approaches to treating ASD, Definium Therapeutics is positioning itself at the forefront of research aimed at improving therapies that address the unique challenges faced by individuals with autism, thus promoting better behavioral and social outcomes.
Contact Information
